The experimental cancer drug regorafenib appears to extend survival slightly in patients with metastatic colorectal cancer, a new trial indicates.
Regorafenib is a so-called multikinase inhibitor, which targets several of the ways cancer develops and grows, researchers said.
"The drug was tested on patients with metastatic colorectal cancer
who had progressed after standard therapies, meaning they had no
treatment options available," lead researcher Dr. Axel Grothey, a
professor of oncology at the Mayo Clinic.
The investigators found that patients taking regorafenib survived an
average of 6.4 months, compared with five months for those receiving a
placebo -- an increase in survival of 29 percent.
In addition, 44 percent of the patients taking regorafenib responded
to the drug or had their cancer slowed, compared with 15 percent of the
patients receiving placebo, they reported.
Ref : http://gicasym.org/GastrointestinalCancersSymposiumDailyNews/GI385.aspx
